Trial Profile
A study to evaluate the efficacy of gefitinib according to body surface area in patients with non-small cell lung cancer harboring an EGFR mutation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Nov 2015
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 19 Nov 2015 New trial record